Answers are grounded in this paper and cite their sources.
New disease-modifying drug classes have shown substantial benefits against major adverse cardiovascular events and mortality in heart failure over the past decade.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zuin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: